TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04000815

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C Type Natriüretic Peptide
Description: C Type Natriuretic Peptide will be measured with elisa method

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C Type Natriüretic Peptide
Description: C Type Natriuretic Peptide will be measured with elisa method

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C Type Natriüretic Peptide
Description: C Type Natriuretic Peptide will be measured with elisa method
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00448019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV over 30 minutes daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2 IV over 30 minutes daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
Study: NCT00804180

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Injection Anxiety Counseling
Description: This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
Study: NCT02514876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foresight ICE System
Description: The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
Study: NCT00875030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate sachets
Description: single dose 50 mg (2 X 25 mg) artesunate sachets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsuamoon
Description: single dose 50 mg arsuamoon tablet
Study: NCT02898168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WA group
Description: Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional rehabilitation therapy and gait training without WA.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00995241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 800 mg / 24 hours.
Study: NCT01700244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implant
Study: NCT01425060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive management program
Description: The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
Study: NCT05278325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Description: Two planned phone call between clinical controls
Study: NCT02517684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive enteral nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Study: NCT03197883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Restoring lipid balm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanser
Description: Moisturizing facial cleanser

Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser
Description: Moisturizing facial cleanser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: SPF (Sun Protection Factor) 50 sunscreen

Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen
Description: SPF (Sun Protection Factor) 50 sunscreen
Study: NCT01240291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dipeptiven
Description: Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
Study: NCT04370639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuFlow sensor
Description: AccuFlow sensor will be worn and survey completed
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study: NCT04370639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
Study: NCT02882945

Intervention type: OTHER
Intervention: Group A
Description: 150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.

Intervention type: OTHER
Intervention: Group B
Description: 200 cases of type 2 DM without complications were enrolled in the study.

Intervention type: OTHER
Intervention: Group C
Description: 120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
Study: NCT03217903

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myelogram
Description: Bone marrow aspiration after 3 cycles of Azacytidine treatment
Study: NCT01751048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3
Description: LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3
Description: LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3
Description: LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPL-SE
Description: Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SE
Description: Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
Study: NCT02255708

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Neuromuscular Facilitation - PNF

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Neuromuscular Facilitation - PNF
Study: NCT03325192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid pleurodesis protocol
Description: * The pleural space will be evacuated completely through the newly placed IPC~* 20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * The pleural space will be evacuated completely through the newly placed IPC~* Only placebo (normal saline) will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis.
Study: NCT01450189

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV prevention messages
Description: A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV prevention messages
Description: A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV prevention messages
Description: A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI: Information-Motivation-Behavioral Skills Model
Description: The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI: Information-Motivation-Behavioral Skills Model
Description: The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: raltegravir (400 mg) administered orally twice daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate
Description: emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
Study: NCT03799653

Intervention type: OTHER
Intervention: No intervention
Description: This is a prospective observational study, and there is no intervention.
Study: NCT02157636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0610
Study: NCT01921062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
Study: NCT03513445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naropin
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study: NCT02830438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear wave elastography
Description: Ultrasound technique of the kidneys to assess wave elastography.
Study: NCT01230177

Intervention type: DRUG
Intervention: etanercept (genetical recombination)
Description: 10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
Study: NCT02194257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-cyclohexane ambroxol oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzyl ambroxol oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol lozenge
Study: NCT01659580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 high dose
Description: 225mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 Low dose
Description: 150mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanqi+Bingpian
Description: 225 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 225mg bid
Study: NCT00075478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Given PO
Study: NCT02194257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol lozenge
Study: NCT01534182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta - 1a (IFN)
Description: 44 mcg subcutaneously three times a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate (GA)
Description: 20 mg subcutaneously once a day
Study: NCT01479283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered.
Study: NCT00770146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mipomersen sodium
Description: 200 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
Study: NCT02158364

Intervention type: DRUG
Intervention: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Description: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Study: NCT01782001

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: vitamin A with placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A and zinc
Description: combination of vitamin A and zinc supplements
Study: NCT01592656

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax. At baseline, after 1 month and after 6 months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax. At baseline, after 1 month and after 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lung compliance measurement
Description: At baseline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lung compliance measurement
Description: At baseline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation (Respironics)
Description: Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 \> 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
Study: NCT03027284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study: NCT02915874

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT00075478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo transplantation
Study: NCT02140398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Currettage
Description: Only Laparoscopic ovarian drilling without endometrial currettage will be performed
Study: NCT01645995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reformulated products
Description: Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional products
Description: Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
Study: NCT03439982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: FMT processed from routinely screened donors
Study: NCT03974438

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Superficial dry needling / Acupunture
Description: Se arm-description.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial dry needling / Acupunture
Description: Se arm-description.
Study: NCT01024166

Intervention type: BEHAVIORAL
Intervention: Questionnaire and Review Session
Description: Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.

Intervention type: BEHAVIORAL
Intervention: Questionnaire and Review Session
Description: Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.

Intervention type: BEHAVIORAL
Intervention: Questionnaire and Review Session
Description: Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
Study: NCT04289532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-RWY
Description: 99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .